Atomwise Stock

atomwise.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $151.49MM

Atomwise is the developer of first deep learning technology designed for structure-based small molecule drug discovery.

Register for Details

For more details on financing and valuation for Atomwise, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Atomwise.

Register Today

Team

Management Team

Izhar Wallach Ph.D
Co-Founder & Chief Technology Officer
Han Lim
Vice President and Global Head of Partnering
Abraham Heifets Ph.D
Co-Founder & Chief Executive Officer

Board Members

Gavin Teo
B Capital Group
Adam Seabrook
B Capital Group
Kiersten Stead Ph.D
Monsanto Growth Ventures
Matthew Ocko
Data Collective

Other companies like Atomwise in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Atomwise raises $123 million to accelerate drug discovery with AI
Atomwise, a company leveraging AI and machine learning to accelerate drug discovery, has raised $123 million in venture capital.
Atomwise's X-37 spinout gets $14.5 million to launch AI discovery efforts
The folks behind Atomwise's spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures
Atomwise Raises $45 Million Series A to Become the Preferred Artificial Intelligence Partner for the Global Pharmaceutical Industry
Updated on: Oct 2, 2023